search
Back to results

Personalized Exercise Therapy and Self-management Support for Patients With Multimorbidity (MOBILIZE)

Primary Purpose

Osteoarthritis, Knee, Osteoarthritis, Hip, Heart Failure

Status
Active
Phase
Not Applicable
Locations
Denmark
Study Type
Interventional
Intervention
Personalized exercise therapy and self-management support program
Usual care
Sponsored by
University of Southern Denmark
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Osteoarthritis, Knee focused on measuring Exercise, Self-management, Clinical Trial, Multimorbidity, Evaluation

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • At least two of the following conditions: OA (knee or hip), COPD, heart condition (HF or CHD), hypertension, T2DM, depression (having other comorbidities does not exclude a patient)
  • Adults aged 18 years or above
  • Able to walk 3 meters without any assistance
  • A score of 3 or above on the Bayliss' Disease Burden: Morbidity Assessment by Self- Report scale for at least one of the conditions listed above and a score of 2 or above for at least one of the other listed conditions
  • Willingness and ability to participate in a 12-week supervised exercise therapy and self- management support program twice a week

Exclusion Criteria:

  • Participation in supervised systematic exercise for one of their diseases within the last 3 months
  • Patients with an unstable health condition or at risk of serious adverse events as evaluated by a medical specialist
  • Patients categorized as Class IV on the New York Heart Association (NYHA) Functional Classification scale
  • Terminal patients and patients with life expectancy of less than 12 months
  • Patients with psychosis disorders, post-traumatic stress disorder, Obsessive Compulsive Disorder, attention deficit hyperactivity disorder, autism, anorexia nervosa/bulimia nervosa and patients with an abuse
  • Other reasons (unable to understand Danish, mentally unable to participate, etc.)

Sites / Locations

  • Holbæk Sygehus
  • Læge Poul Erik Holst
  • Lægehuset Tolskovvej
  • Department of Orthopedics, Zealand University Hospital
  • Community Clinic
  • Department of Orthopaedic Surgery, Næstved Hospital
  • Department of Pulmonology, Næstved Hospital
  • Lægehuset Ostenfeldt
  • Psychiatric Clinic Næstved
  • Community Psychiatry Roskilde
  • Department of Cardiology, Zealand University Hospital
  • Lægerne Algade 17
  • Department of Cardiology and Endocrinology, Slagelse Hospital
  • Lægerne Reventlow og Wolfhagen
  • Psychiatric Hospital West, Slagelse
  • Nykøbing Falster County Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Personalized exercise therapy and self-management program in addition to usual care

Usual care alone

Arm Description

Participants randomized to the personalized exercise therapy and self-management support program will participate in a 12-week program tailored to people with multimorbidity at one of the intervention sites. The program will consist of 24 exercise therapy and self-management sessions distributed across the program (twice weekly, each lasting around 1.5 hour). Furthermore, this group will receive the treatment described under usual care below.

Usual care is the care that the participants would receive had they not participated in the study, i.e. treatments or services that are routinely provided in the settings from which the participants are recruited. Participants will continue their current treatment, if needed, and be allowed to receive other treatments if their general practitioner or specialist finds it relevant for their particular comorbidities.

Outcomes

Primary Outcome Measures

EQ-5D-5L, the descriptive index
The descriptive index of the EuroQol-5 Domain 5-level questionnaire (EQ-5D-5L) measures the patient's self-rated health status. Ranging from -0.624 to 1, higher is better. This will also allow for a later cost-effectiveness analysis. Assessed at baseline, 4, 6 and 12 months. All visits (baseline, 4, 6 and 12 months) will be included in the analysis.

Secondary Outcome Measures

6-minute walk test
The walking distance covered over a time of 6 minutes. Assessed at baseline, 4 and 12 months.
Burden of illness measure
The burden of illness measure developed by Bayliss et al. measures how much illness affects the individual's daily activities (on a 1-5 scale for each individual condition, higher is worse, summed to a total score for all conditions, with an upper limit depending on the number of conditions included). Assessed at baseline, 4, 6 and 12 months.
30-second chair-stand test
The number of chair stands completed in 30 seconds. Assessed at baseline, 4 and 12 months.
Depression Scale
Personal Health Questionnaire Depression Scale (PHQ-8). Ranging from 0-24 points, higher is more severe depression. Assessed at baseline, 4, 6 and 12 months.
Anxiety
General Anxiety Disorder-7 (GAD-7). Ranging from 0-21, higher is more severe anxiety. Assessed at baseline, 4, 6 and 12 months.
Self-Efficacy
Self-Efficacy for Managing Chronic Disease 6-item Scale. Mean of 6 items, ranging from 1 to 10, higher scores indicating higher self-efficacy. Assessed at baseline, 4, 6 and 12 months.
Overall functioning and disability
12-item WHO Disability Assessment Schedule 2.0 (WHODAS 2.0). Ranging from 0 (no disability) to 100 (full disability). Assessed at baseline, 4, 6 and 12 months.
Adverse events
Adverse events (AE) and serious adverse events (SAE) will be recorded at all follow-ups by asking the participants about potential AEs using open-probe questioning to ensure that all AEs are recorded. Furthermore, the medical records of the patients will be checked at the primary endpoint (12 months) for all AEs occurring from inclusion until the 12 months follow-up. AEs will be classified according to the Food and Drug Administration definition of an SAE and recorded, categorized and assessed for severity independent of whether or not there is a causal relationship with study treatments. Assessed at 4, 6 and 12 months.
Steps per day
Objectively measured physical activity assessed using combined wearable thigh and wrist accelerometers. Assessed at baseline, 4 and 12 months.
Minutes/day spent being physically active with at least light intensity
Objectively measured physical activity assessed using combined wearable thigh and wrist accelerometers. Assessed at baseline, 4 and 12 months.
EQ-5D-5L, the subscale EQ VAS
The EQ visual analogue scale (EQ VAS) evaluates the patient's self-rated health on a 0-100 vertical visual analogue scale, higher score is better. Assessed at baseline, 4, 6 and 12 months.
Mortality
Mortality will be recorded at 12 months via medical records

Full Information

First Posted
November 2, 2020
Last Updated
October 13, 2023
Sponsor
University of Southern Denmark
Collaborators
Naestved Hospital, Slagelse Hospital, Lolland Municipality, Roskilde Municipality, Psychiatric Hospital West, Slagelse, Næstved, Slagelse and Ringsted Hospitals' Research Fund, Association of Danish Physiotherapists, The Danish Health Confederation through the Development and Research Fund, European Research Council, Holbaek Sygehus, Nykøbing Falster County Hospital, FysioDanmark Holbæk, Zealand University Hospital, Lægerne Reventlow og Wolfhagen, Slagelse, Lægerne Algade 17, Roskilde
search

1. Study Identification

Unique Protocol Identification Number
NCT04645732
Brief Title
Personalized Exercise Therapy and Self-management Support for Patients With Multimorbidity
Acronym
MOBILIZE
Official Title
Improving Health in People With Multimorbidity: a Paradigm Shift in Health Care From Disease-based Curative Models to Personalized Exercise Therapy and Self-management
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
November 1, 2021 (Actual)
Primary Completion Date
July 31, 2024 (Anticipated)
Study Completion Date
July 31, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Southern Denmark
Collaborators
Naestved Hospital, Slagelse Hospital, Lolland Municipality, Roskilde Municipality, Psychiatric Hospital West, Slagelse, Næstved, Slagelse and Ringsted Hospitals' Research Fund, Association of Danish Physiotherapists, The Danish Health Confederation through the Development and Research Fund, European Research Council, Holbaek Sygehus, Nykøbing Falster County Hospital, FysioDanmark Holbæk, Zealand University Hospital, Lægerne Reventlow og Wolfhagen, Slagelse, Lægerne Algade 17, Roskilde

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Chronic conditions such as knee or hip osteoarthritis (OA), chronic obstructive pulmonary disease (COPD), heart failure (HF), coronary heart disease (CHD), hypertension, type 2 diabetes mellitus (T2DM) and depression are among the leading causes of global disability and affect hundreds of millions of people around the world. In recent years, multimorbidity, commonly defined as the co-occurrence of at least two chronic conditions, has also gained interest due to its substantial impact on the person and society. Despite the significant burden of multimorbidity, little is known about how to treat this effectively. A 2016 Cochrane systematic review found that interventions targeting populations with specific combinations of conditions and addressing specific problems such as functional difficulties may be more effective. Exercise therapy is a treatment addressing functional limitations that is a safe and effective treatment of at least 26 chronic conditions, including OA, HF, CHD, hypertension, T2DM, COPD and depression. Furthermore, self-management support is increasingly recognized as an essential component of interventions to improve outcomes in patients living with multimorbidity and to support the long-term adherence to exercise. A new systematic review found that exercise seems effective in people with multimorbidity (the conditions included in the current study), however highlighting the need for further high-quality RCTs. The aim of this randomized controlled trial (RCT) is to investigate the effects of a personalized exercise therapy and self-management support program in addition to usual care on self-reported, objectively measured and physiological outcomes in people with multimorbidity (i.e. at least two of the following conditions: OA (knee or hip), heart condition (HF or CHD), hypertension, T2DM, COPD and depression). The primary endpoint is 12 months, but 4- and 6-month follow-ups are included as well and a 12-month health economic evaluation of the program will be conducted. Prior to the RCT, a feasibility trial of 20 people with multimorbidity, all undergoing the personalized exercise therapy and self-management support program, will be conducted using the same methods as in the RCT, but primarily focusing on feasibility outcomes (recruitment, retention, adherence to treatment, burden of outcomes, improvements in outcomes, adverse events). This will start recruitment in Feb 2021 and end August 2021. The MOBILIZE project has received funding from several foundations, including the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (grant agreement No 801790).
Detailed Description
Chronic conditions such as knee or hip osteoarthritis (OA), chronic obstructive pulmonary disease (COPD), heart failure (HF), coronary heart disease (CHD), hypertension, type 2 diabetes mellitus (T2DM) and depression are among the leading causes of global disability and affect hundreds of millions of people around the world. In recent years, multimorbidity, commonly defined as the co-occurrence of at least two chronic conditions, has also gained interest due to its substantial impact on the person and society. In general, multimorbidity affects more than half of all people with chronic conditions. Two out of three people with OA have comorbidities, with HF, CHD, hypertension, T2DM, COPD and depression being some of the most common. People with multimorbidity account for 78% of all consultations in primary care and multimorbidity is associated with poorer function and quality of life, depression, intake of multiple drugs and increased health care utilization, with some studies demonstrating an almost exponential relationship between the number of chronic conditions and their health care costs. Furthermore, we know from qualitative research that treating one condition at a time is inconvenient, inefficient and unsatisfactory for the person with the chronic conditions and his or her health care provider. Most research so far has excluded people with multimorbidity, due to its focus on only one specific condition, and most of the health care sector manages each individual condition on its own instead of the person, highlighting the negative impact of the current disease-based curative models on multimorbidity. With a population that is ageing, and a significant number of people with multimorbidity being younger than 65 years of age, the proportion of people with multimorbidity is increasing rapidly, emphasizing the need to take action to deal with the increasing burden of chronic conditions and multimorbidity through treatment and prevention. Identifying and developing effective and affordable treatment strategies to deal with the global burden of chronic conditions and multimorbidity is a major focus of modern health care around the world. Despite the significant burden of multimorbidity, little is known about how to treat this effectively. A 2016 Cochrane systematic review found that interventions targeting populations with specific combinations of conditions and addressing specific problems such as functional difficulties may be more effective. A treatment addressing functional limitations that is able to improve symptoms in at least 26 chronic conditions, including OA, HF, CHD, hypertension, T2DM, COPD and depression is readily available. This treatment is exercise therapy, which is effective, safe and supported by substantial evidence in patients with knee and hip OA, HF and CHD, hypertension, T2DM, COPD, depression and a range of other chronic conditions. A new systematic review found that exercise seems effective in people with multimorbidity (the conditions included in the current study), however highlighting the need for further high-quality RCTs. Furthermore, self-management support is increasingly recognized as an essential component of interventions to improve outcomes in patients living with multimorbidity. There is increasing evidence that effective management of multimorbidity requires the active participation by patients in the care process. Self-management support interventions have been shown to change health behaviors, improve health status, and reduce health care utilization and costs. Self-management support is centered on enabling patients to develop a set of behavioral skills and abilities to help them navigate a range of disease management tasks across different chronic conditions. In an RCT of people with knee OA, published in the New England Journal of Medicine, we found that 3 out of 4 patients eligible for total knee replacement improved enough from self-management support, supervised exercise therapy and other non-surgical treatments to postpone surgery for at least one year. Furthermore, in patients with T2DM, 56% did not take antidiabetic medication after 1 year of supervised exercise therapy, self-management support and diet. Together, these studies indicate the potential of combining exercise, self-management and other treatments to reduce the need for surgery and medication. A recent cohort study found that an eight-week exercise and self-management program demonstrated similar improvements in health outcomes for people with OA and the comorbidities included in the current study as for people without comorbidities. Altogether, this highlights exercise therapy and self-management support as viable treatment options for people with multimorbidity, but the evidence supporting this is of low quality and more high-quality RCTs are needed to improve care for the millions of people suffering from multimorbidity worldwide. The overall aim of the MOBILIZE project is to empower patients with multimorbidity to take a more active role in their health care through a personalized exercise therapy and self-management support program so that they may reduce symptoms of the individual conditions, increase quality of life and physical function and prevent development of other chronic conditions. To ensure relevance to the patients and the health care system and to make sure that the project is implementable in clinical practice afterwards, strong interdisciplinary collaboration involving many different scientific methodologies and a high degree of patient involvement throughout the entire research process are at the heart of the project. The MOBILIZE project has received funding from several foundations, including the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (grant agreement No 801790). Building on the Medical Research Council's framework for the development and evaluation of complex interventions, the MOBILIZE project has four phases. During the first phase of the project, outcomes and biomarkers that predict better health outcome from different types of exercise therapy and exercise characteristics associated with a better outcome in people with different combinations of chronic conditions will be identified through exploratory observational cohort studies of people with osteoarthritis who have undergone an 8-week exercise therapy and education program in Denmark (GLA:D) as well as scoping reviews, systematic reviews and meta-analyses that summarize the existing evidence. Subsequently, in phase 2, a 12-week exercise therapy and self-management support program will be developed based on existing recommendations for exercise and strategies to facilitate behavioral changes. To ensure a high degree of patient and provider involvement, focus group interviews will be conducted with patients with multimorbidity, health care providers and other relevant stakeholders to acquire their views and perspectives on multimorbidity and exercise. Once this phase is completed, the exercise therapy and self-management support program will be tested in a feasibility trial involving 20 patients with multimorbidity (recruited from Feb 2021 and onwards). The same procedures and outcomes as in the subsequent RCT will be used, and data will be collected at baseline and after the 12-week intervention. The feasibility trial will primarily focus on feasibility outcomes (recruitment, retention, adherence to treatment, burden of outcomes, improvements in outcomes, adverse events), using a red/amber/green traffic light system, guiding the progression to the subsequent RCT. Experiences from the feasibility trial will be used to evaluate and implement any adjustments that need to be made prior to commencing the RCT (described in details in the current trial registration). The RCT corresponds to phase 3, while phase 4 focuses on developing a model for implementation of the personalized exercise therapy and self-management support program in clinical practice, if supported by the study findings. The aim of the RCT described in this clinical trial registration is to investigate the effects of a personalized exercise therapy and self-management support program in addition to usual care on self-reported, objectively measured and physiological outcomes in people with multimorbidity (i.e. at least two of the following conditions: OA (knee or hip), heart condition (HF or CHD), hypertension, T2DM, COPD and depression). The primary endpoint is 12 months, but 4- and 6-month follow-ups are included as well and a 12-month health economic evaluation of the program will be conducted. The 4-month follow-up corresponds to immediately after the intervention, including the time it takes to conduct the baseline measurements and be enrolled in the group-based program. The primary study hypothesis is that a personalized exercise therapy and self-management support program in addition to usual care will improve quality of life more than usual care alone when measured at 12 months with concurrent positive effects on secondary outcomes. Furthermore, it is hypothesized that the program will be cost-effective at 12 months. People will be recruited via the recruitment centers mentioned in this registration as well as via self-referral (Facebook posts, newspaper articles and flyers). People who only fulfil some of the eligibility criteria (aged 18 years or above, at least two of the relevant conditions and do not have psychosis disorders, post-traumatic stress disorder, Obsessive Compulsive Disorder, attention deficit hyperactivity disorder, autism, anorexia nervosa/bulimia nervosa or an abuse or other reasons for exclusion) or people fulfilling all eligibility criteria, but unwilling to participate in the RCT, will be offered participation in an observational cohort study where only the self-reported outcomes are completed. Recruitment for the cohort will start and end with the recruitment for the RCT.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Osteoarthritis, Knee, Osteoarthritis, Hip, Heart Failure, Coronary Heart Disease, Hypertension, Type2 Diabetes, Chronic Obstructive Pulmonary Disease, Depression
Keywords
Exercise, Self-management, Clinical Trial, Multimorbidity, Evaluation

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
The RCT is a pragmatic, parallel-group, superiority RCT (1:1 ratio)
Masking
InvestigatorOutcomes Assessor
Masking Description
Study investigators, outcome assessors and the statistician will be blinded to randomization. Furthermore, a blinded interpretation of the study results will be conducted
Allocation
Randomized
Enrollment
228 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Personalized exercise therapy and self-management program in addition to usual care
Arm Type
Experimental
Arm Description
Participants randomized to the personalized exercise therapy and self-management support program will participate in a 12-week program tailored to people with multimorbidity at one of the intervention sites. The program will consist of 24 exercise therapy and self-management sessions distributed across the program (twice weekly, each lasting around 1.5 hour). Furthermore, this group will receive the treatment described under usual care below.
Arm Title
Usual care alone
Arm Type
Active Comparator
Arm Description
Usual care is the care that the participants would receive had they not participated in the study, i.e. treatments or services that are routinely provided in the settings from which the participants are recruited. Participants will continue their current treatment, if needed, and be allowed to receive other treatments if their general practitioner or specialist finds it relevant for their particular comorbidities.
Intervention Type
Behavioral
Intervention Name(s)
Personalized exercise therapy and self-management support program
Intervention Description
See description under Arms
Intervention Type
Other
Intervention Name(s)
Usual care
Intervention Description
See description under Arms
Primary Outcome Measure Information:
Title
EQ-5D-5L, the descriptive index
Description
The descriptive index of the EuroQol-5 Domain 5-level questionnaire (EQ-5D-5L) measures the patient's self-rated health status. Ranging from -0.624 to 1, higher is better. This will also allow for a later cost-effectiveness analysis. Assessed at baseline, 4, 6 and 12 months. All visits (baseline, 4, 6 and 12 months) will be included in the analysis.
Time Frame
Primary endpoint: Change from baseline to 12 months
Secondary Outcome Measure Information:
Title
6-minute walk test
Description
The walking distance covered over a time of 6 minutes. Assessed at baseline, 4 and 12 months.
Time Frame
Primary endpoint: Change from baseline to 12 months
Title
Burden of illness measure
Description
The burden of illness measure developed by Bayliss et al. measures how much illness affects the individual's daily activities (on a 1-5 scale for each individual condition, higher is worse, summed to a total score for all conditions, with an upper limit depending on the number of conditions included). Assessed at baseline, 4, 6 and 12 months.
Time Frame
Primary endpoint: Change from baseline to 12 months
Title
30-second chair-stand test
Description
The number of chair stands completed in 30 seconds. Assessed at baseline, 4 and 12 months.
Time Frame
Primary endpoint: Change from baseline to 12 months
Title
Depression Scale
Description
Personal Health Questionnaire Depression Scale (PHQ-8). Ranging from 0-24 points, higher is more severe depression. Assessed at baseline, 4, 6 and 12 months.
Time Frame
Primary endpoint: Change from baseline to 12 months
Title
Anxiety
Description
General Anxiety Disorder-7 (GAD-7). Ranging from 0-21, higher is more severe anxiety. Assessed at baseline, 4, 6 and 12 months.
Time Frame
Primary endpoint: Change from baseline to 12 months
Title
Self-Efficacy
Description
Self-Efficacy for Managing Chronic Disease 6-item Scale. Mean of 6 items, ranging from 1 to 10, higher scores indicating higher self-efficacy. Assessed at baseline, 4, 6 and 12 months.
Time Frame
Primary endpoint: Change from baseline to 12 months
Title
Overall functioning and disability
Description
12-item WHO Disability Assessment Schedule 2.0 (WHODAS 2.0). Ranging from 0 (no disability) to 100 (full disability). Assessed at baseline, 4, 6 and 12 months.
Time Frame
Primary endpoint: Change from baseline to 12 months
Title
Adverse events
Description
Adverse events (AE) and serious adverse events (SAE) will be recorded at all follow-ups by asking the participants about potential AEs using open-probe questioning to ensure that all AEs are recorded. Furthermore, the medical records of the patients will be checked at the primary endpoint (12 months) for all AEs occurring from inclusion until the 12 months follow-up. AEs will be classified according to the Food and Drug Administration definition of an SAE and recorded, categorized and assessed for severity independent of whether or not there is a causal relationship with study treatments. Assessed at 4, 6 and 12 months.
Time Frame
Primary endpoint: 12 months
Title
Steps per day
Description
Objectively measured physical activity assessed using combined wearable thigh and wrist accelerometers. Assessed at baseline, 4 and 12 months.
Time Frame
Primary endpoint: Change from baseline to 12 months
Title
Minutes/day spent being physically active with at least light intensity
Description
Objectively measured physical activity assessed using combined wearable thigh and wrist accelerometers. Assessed at baseline, 4 and 12 months.
Time Frame
Primary endpoint: Change from baseline to 12 months
Title
EQ-5D-5L, the subscale EQ VAS
Description
The EQ visual analogue scale (EQ VAS) evaluates the patient's self-rated health on a 0-100 vertical visual analogue scale, higher score is better. Assessed at baseline, 4, 6 and 12 months.
Time Frame
Primary endpoint: Change from baseline to 12 months
Title
Mortality
Description
Mortality will be recorded at 12 months via medical records
Time Frame
Primary endpoint: 12 months
Other Pre-specified Outcome Measures:
Title
Isometric knee-extension strength
Description
Isometric knee-extension strength assessed using a hand-held dynamometer. Assessed at baseline, 4 and 12 months.
Time Frame
Primary endpoint: Change from baseline to 12 months
Title
Balance
Description
Tandem 30-second balance test. Assessing balance in 30-second with 10 seconds in each of the 3 different positions (parallel feet, semi-tandem and tandem stand) resulting in a score from 0-30, higher is better. Assessed at baseline, 4 and 12 months.
Time Frame
Primary endpoint: Change from baseline to 12 months
Title
Pain (yes/no) in left and right knee and hip + worst joint if more than one
Description
Left/right knee/hip pain + worst joint if more than one. Assessed at baseline, 4, 6 and 12 months.
Time Frame
Primary endpoint: Change from baseline to 12 months
Title
Stress
Description
Perceived Stress Scale (4-item version). Ranging from 0-16, higher is more stressed. Assessed at baseline, 4, 6 and 12 months.
Time Frame
Primary endpoint: Change from baseline to 12 months
Title
Systolic and diastolic blood pressure
Description
Blood pressure after 5 minutes of rest. Assessed at baseline, 4 and 12 months.
Time Frame
Primary endpoint: Change from baseline to 12 months
Title
Concentration of cholesterol (HDL and LDL) and triglyceride
Description
Levels of cholesterol (HDL and LDL) and triglyceride. Assessed at baseline and 4 months.
Time Frame
Primary endpoint: Change from baseline to 4 months
Title
Concentration of Fasting glucose
Description
Levels of fasting glucose. Assessed at baseline and 4 months.
Time Frame
Primary endpoint: Change from baseline to 4 months
Title
Concentration of Fasting insulin
Description
Levels of fasting insulin. Assessed at baseline and 4 months.
Time Frame
Primary endpoint: Change from baseline to 4 months
Title
Concentration of HbA1c
Description
Levels of HbA1c. Assessed at baseline and 4 months.
Time Frame
Primary endpoint: Change from baseline to 4 months
Title
Concentration of high-sensitivity C-reactive protein (hs-CRP)
Description
Levels of the inflammatory marker high-sensitivity C-reactive protein (hs-CRP). Assessed at baseline and 4 months.
Time Frame
Primary endpoint: Change from baseline to 4 months
Title
Concentration of Tumor necrosis factor (TNF)
Description
Levels of the inflammatory marker Tumor necrosis factor (TNF). Assessed at baseline and 4 months.
Time Frame
Primary endpoint: Change from baseline to 4 months
Title
Concentration of Interleukin 6 (IL-6)
Description
Levels of the inflammatory marker Interleukin 6 (IL-6). Assessed at baseline and 4 months.
Time Frame
Primary endpoint: Change from baseline to 4 months
Title
Concentration of Interleukin-1 receptor antagonist (IL-1ra)
Description
Levels of the inflammatory marker Interleukin-1 receptor antagonist (IL-1ra). Assessed at baseline and 4 months.
Time Frame
Primary endpoint: Change from baseline to 4 months
Title
Weight
Description
Weight in kg. measured with a scale. Assessed at baseline, 4 and 12 months.
Time Frame
Primary endpoint: Change from baseline to 12 months
Title
Adapted Fried Frailty and pre-frailty criteria
Description
Frailty and pre-frailty assessed by the Adapted Fried Frailty and pre-frailty criteria. Assessed at baseline, 4 and 12 months.
Time Frame
Primary endpoint: Change from baseline to 12 months
Title
Fatigue
Description
One-item self-reported fatigue. Assessed at baseline, 4, 6 and 12 months.
Time Frame
Primary endpoint: Change from baseline to 12 months
Title
Disease-specific treatment
Description
Self-reported disease-specific treatment. Assessed at baseline, 4, 6 and 12 months.
Time Frame
Primary endpoint: Change from baseline to 12 months
Title
Knee/hip pain, VAS
Description
Average knee/hip pain during the last 7 days on a 0-100 visual analogue scale for worst joint (higher is worse pain, only for patients reporting knee/hip pain). Assessed at baseline, 4, 6 and 12 months.
Time Frame
Primary endpoint: Change from baseline to 12 months
Title
Patient Acceptable Symptom State (PASS)
Description
"Thinking about your quality of life, would you consider your current health as satisfying? With quality of life, you should consider your activities of daily living, sport and recreational activities, personal care, level of pain, and any anxiety or depression." Answered by "yes" or "no". Assessed at 4, 6 and 12 months.
Time Frame
Primary endpoint: 12 months
Title
Patient-reported treatment failure
Description
Only answered by patients answering "no" to PASS. "Would you consider your current state as being so unsatisfactory that you consider the treatment to have failed?". Answered by "yes" or "no". Assessed at 4 and 12 months.
Time Frame
Primary endpoint: 12 months.
Title
Adherence
Description
Adherence to intervention protocol of the study assessed as the number of exercise and self-management support sessions attended out of the total number of sessions available. Assessed at 4 months.
Time Frame
Primary endpoint: 4 months
Title
Other treatment during follow-up
Description
Assessed by asking the patient about changes in their pharmacological treatment as well as any other treatments that they have received outside the study since the last assessment. If the patient answers yes, questions on details of the changes and other treatments will be asked. Assessed at 4, 6 and 12 months.
Time Frame
Primary endpoint: 12 months
Title
Work status
Description
"What is your current work status?" The patients choose one of several categories (e.g. "Working", "On sick leave, full time" and "Pensioner". Assessed at baseline, 4, 6 and 12 months.
Time Frame
12 months.
Title
Smoking
Description
"How many cigarettes did you smoke in the last 7 days?" Assessed at baseline, 4, 6 and 12 months.
Time Frame
Primary endpoint: 12 months
Title
Questionnaire burden (only feasibility study)
Description
"Did you find the questionnaire so burdensome that you would not participate in the study again?" Answered "yes"/"no". Assessed at baseline and 4 months.
Time Frame
Primary endpoint: 4 months
Title
Assessment burden (only feasibility study)
Description
"Did you find the assessments so burdensome that you would not participate in the study again?" Answered "yes"/"no". Assessed at baseline and 4 months.
Time Frame
Primary endpoint: 4 months
Title
Isometric handgrip strength
Description
Isometric handgrip strength assessed using a hand-held dynamometer. Assessed at baseline, 4 and 12 months.
Time Frame
Primary endpoint: Change from baseline to 12 months
Title
Multimorbidity Treatment Burden
Description
Multimorbidity Treatment Burden Questionnaire. Ranging from 0-100, higher is worse. Assessed at baseline, 4, 6 and 12 months.
Time Frame
Primary endpoint: Change from baseline to 12 months
Title
Short form of Patient Activation Measure (PAM)
Description
Short form of Patient Activation Measure (PAM). Ranging from 0-100, higher scores indicating higher levels of patient activation. Assessed at baseline, 4, 6 and 12 months.
Time Frame
Primary endpoint: Change from baseline to 12 months
Title
Bodily pain
Description
The number of self-reported body sites with pain in the previous 24 hours reported on a region-divided body chart of the front (A) and back (B) sides of the body. Assessed at baseline, 4, 6 and 12 months.
Time Frame
Primary endpoint: Change from baseline to 12 months
Title
Sedentary behaviour
Description
Daily sedentary behaviour (one item). Assessed at baseline, 4, 6 and 12 months.
Time Frame
Primary endpoint: Change from baseline to 12 months
Title
Individual items from the 12-item WHODAS 2.0
Description
The 12 individual items from WHO Disability Assessment Schedule 2.0. Ranging from 1 to 5, higher score is worse. Assessed at baseline, 4, 6 and 12 months.
Time Frame
Primary endpoint: Change from baseline to 12 months
Title
Spirometry (FEV1)
Description
Spirometry (MedikroPro) will be used to measure forced expiratory volume in first second in liter (FEV1).Assessed at baseline.
Time Frame
Only assessed at baseline.
Title
Self-reported physical activity level
Description
Weekly physical activity (two items). Assessed at baseline, 4, 6 and 12 months.
Time Frame
Primary endpoint: Change from baseline to 12 months
Title
Global Perceived Effect (GPE)
Description
Global Perceived Effect (GPE) for physical activity level, activities of daily living and quality of life. Answered on 7-point Likert scale ranging from (1) "Much better, an important improvement" to (7) "Much worse, an important deterioration", higher score is worse. Assessed at 4, 6 and 12 months.
Time Frame
Primary endpoint: 12 months
Title
Falls
Description
Over the last 4 months, have you ever been falling? "2months" at 6-month follow-up and "6 months" at the 12-month follow-up. (A fall is defined as an event resulting in you inadvertently coming to rest on the ground or another lower level, with or without loss of consciousness or injury). Never; Once; Twice; Three times or more. Assessed at 4, 6 and 12 months.
Time Frame
Primary endpoint: 12 months
Title
Fear of falling
Description
How concerned are you that you might fall? Not at all concerned; Somewhat concerned, Fairly concerned, Very concerned. Assessed at 4, 6 and 12 months.
Time Frame
Primary endpoint: 12 months
Title
Sedentary activity: Time spent on sedentary activities
Description
Objectively measured physical activity assessed using combined wearable thigh and wrist accelerometers. Assessed at baseline, 4 and 12 months.
Time Frame
Primary endpoint: Change from baseline to 12 months
Title
Light physical activity: Time spent on light intensity activities
Description
Objectively measured physical activity assessed using combined wearable thigh and wrist accelerometers. Assessed at baseline, 4 and 12 months.
Time Frame
Primary endpoint: Change from baseline to 12 months
Title
Moderate physical activity: Time spent on moderate intensity activities
Description
Objectively measured physical activity assessed using combined wearable thigh and wrist accelerometers. Assessed at baseline, 4 and 12 months.
Time Frame
Primary endpoint: Change from baseline to 12 months
Title
Vigorous physical activity: Time spent on vigorous intensity activities
Description
Objectively measured physical activity assessed using combined wearable thigh and wrist accelerometers. Assessed at baseline, 4 and 12 months.
Time Frame
Primary endpoint: Change from baseline to 12 months
Title
Moderate to vigorous physical activity: Time spent on moderate to vigorous intensity activities
Description
Objectively measured physical activity assessed using combined wearable thigh and wrist accelerometers. Assessed at baseline, 4 and 12 months.
Time Frame
Primary endpoint: Change from baseline to 12 months
Title
Adherence to the World Health Organization (WHO) physical activity recommendations, i.e. ≥150 min. MVPA or ≥75 min. VPA weekly activities
Description
Objectively measured physical activity assessed using combined wearable thigh and wrist accelerometers. Assessed at baseline, 4 and 12 months.
Time Frame
Primary endpoint: Change from baseline to 12 months
Title
Sleep, objectively measured
Description
Objectively measured sleep assessed using combined wearable thigh and wrist accelerometers. Assessed at baseline, 4 and 12 months.
Time Frame
Primary endpoint: Change from baseline to 12 months
Title
Sleep quantity, self-reported
Description
Self-reported average sleep quantity. Assessed at baseline, 4, 6 and 12 months.
Time Frame
Primary endpoint: Change from baseline to 12 months
Title
Modified Karolinska Sleep Questionnaire
Description
Sleep quality will be measured by the Modified Karolinska Sleep Questionnaire (4 items). Ranging from 4 to 24, lower is worse sleep quality. Assessed at baseline, 4, 6 and 12 months.
Time Frame
Primary endpoint: Change from baseline to 12 months
Title
Vigorous Intermittent Lifestyle Physical Activity (VILPA): Time spent on VILPA intensity activities
Description
Objectively measured physical activity assessed using combined wearable thigh and wrist accelerometers. Assessed at baseline, 4 and 12 months.
Time Frame
Primary endpoint: Change from baseline to 12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: At least two of the following conditions: OA (knee or hip), COPD, heart condition (HF or CHD), hypertension, T2DM, depression (having other comorbidities does not exclude a patient) Adults aged 18 years or above Able to walk 3 meters without any assistance A score of 3 or above on the Bayliss' Disease Burden: Morbidity Assessment by Self- Report scale for at least one of the conditions listed above and a score of 2 or above for at least one of the other listed conditions Willingness and ability to participate in a 12-week supervised exercise therapy and self- management support program twice a week Exclusion Criteria: Participation in supervised systematic exercise for one of their diseases within the last 3 months Patients with an unstable health condition or at risk of serious adverse events as evaluated by a medical specialist Patients categorized as Class IV on the New York Heart Association (NYHA) Functional Classification scale Terminal patients and patients with life expectancy of less than 12 months Patients with psychosis disorders, post-traumatic stress disorder, Obsessive Compulsive Disorder, attention deficit hyperactivity disorder, autism, anorexia nervosa/bulimia nervosa and patients with dependency disorders Other reasons (unable to understand Danish, mentally unable to participate, etc.)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Søren T Skou, PT, MSc, PhD
Organizational Affiliation
Næstved, Slagelse and Ringsted hospital and University of Southern Denmark
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Uffe Bødtger, MD
Organizational Affiliation
Department of Pulmonology, Næstved Hospital
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Peter Gæde, MD
Organizational Affiliation
Department of Cardiology and Endocrinology, Slagelse Hospital
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Manuel J Bieder, MD
Organizational Affiliation
Department of Orthopaedic Surgery, Næstved Hospital
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Sidse Arnfred, MD
Organizational Affiliation
Psychiatric Hospital West, Slagelse
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Christine Bodilsen, PT, MSc, PhD
Organizational Affiliation
Municipality of Roskilde
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Jan A Overgaard, PT, MSc
Organizational Affiliation
Municipality of Lolland
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Alessio Bricca, MSc, PhD
Organizational Affiliation
Næstved, Slagelse and Ringsted hospital and University of Southern Denmark
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Madalina Jäger, MSc, PhD
Organizational Affiliation
Næstved, Slagelse and Ringsted hospital and University of Southern Denmark
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Christian S Christiansen, MD
Organizational Affiliation
Nykøbing Falster County Hospital
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Anne Merete B Soja, MD, PhD, DMSc
Organizational Affiliation
Holbaek Sygehus
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Niels Eske Bruun, MD
Organizational Affiliation
Department of Cardiology, Zealand University Hospital, Roskilde
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Johan L Reventlow, MD
Organizational Affiliation
Lægerne Reventlow og Wolfhagen, Slagelse
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Andreas Heltberg, MD, PhD
Organizational Affiliation
Lægerne Algade 17, Roskilde
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Lau C Thygesen, MSc, PhD
Organizational Affiliation
University of Southern Denmark
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Poul Erik Holst, MD
Organizational Affiliation
Læge Poul Erik Holst, Holbæk
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Rita M Andersen, MSc
Organizational Affiliation
Psychiatric Clinic Næstved
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Amir Pasha Attarzadeh, MD
Organizational Affiliation
Department of Orthopedics, Zealand University Hospital, Køge
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Mickey T Kongerslev, MSc
Organizational Affiliation
Community Psychiatry Roskilde
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Louise Richelieu, MD
Organizational Affiliation
Lægehuset Tolskovvej, Hvalsø
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Signe Aspelin, MD
Organizational Affiliation
Lægehuset Ostenfeldt, Næstved
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Sille Capion, MD
Organizational Affiliation
Lægehuset Ostenfeldt, Næstved
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Rune F Nielsen, Nurse
Organizational Affiliation
Community Clinic Nakskov
Official's Role
Study Chair
Facility Information:
Facility Name
Holbæk Sygehus
City
Holbæk
Country
Denmark
Facility Name
Læge Poul Erik Holst
City
Holbæk
Country
Denmark
Facility Name
Lægehuset Tolskovvej
City
Kirke Hvalsø
Country
Denmark
Facility Name
Department of Orthopedics, Zealand University Hospital
City
Køge
Country
Denmark
Facility Name
Community Clinic
City
Nakskov
Country
Denmark
Facility Name
Department of Orthopaedic Surgery, Næstved Hospital
City
Næstved
Country
Denmark
Facility Name
Department of Pulmonology, Næstved Hospital
City
Næstved
Country
Denmark
Facility Name
Lægehuset Ostenfeldt
City
Næstved
Country
Denmark
Facility Name
Psychiatric Clinic Næstved
City
Næstved
Country
Denmark
Facility Name
Community Psychiatry Roskilde
City
Roskilde
Country
Denmark
Facility Name
Department of Cardiology, Zealand University Hospital
City
Roskilde
Country
Denmark
Facility Name
Lægerne Algade 17
City
Roskilde
Country
Denmark
Facility Name
Department of Cardiology and Endocrinology, Slagelse Hospital
City
Slagelse
ZIP/Postal Code
4200
Country
Denmark
Facility Name
Lægerne Reventlow og Wolfhagen
City
Slagelse
ZIP/Postal Code
4200
Country
Denmark
Facility Name
Psychiatric Hospital West, Slagelse
City
Slagelse
ZIP/Postal Code
4200
Country
Denmark
Facility Name
Nykøbing Falster County Hospital
City
Slagelse
Country
Denmark

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Data will be made available upon reasonable request after the primary publications have been published.
IPD Sharing Time Frame
Ultimo 2024.
IPD Sharing Access Criteria
Data will be made available upon reasonable request after the primary publications have been published.
IPD Sharing URL
https://osf.io/qk6yg/
Links:
URL
https://osf.io/qk6yg/
Description
Open Science Framework platform for MOBILIZE
URL
https://www.mobilize-project.dk/?lang=en
Description
MOBILIZE webpage

Learn more about this trial

Personalized Exercise Therapy and Self-management Support for Patients With Multimorbidity

We'll reach out to this number within 24 hrs